Skip To Main Content
Adi Barzel on Muck Rack

Adi Barzel

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Adi

Contact Adi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Roads and detours for CAR T cell therapy in autoimmune diseases - Nature Reviews Drug Discovery

|
By Adi Barzel, Stephen Gottschalk, Ricardo Grieshaber-Bouyer, Marko Radic, Marc Scherlinger
| Nature Verified
Abstract Chimeric antigen receptor (CAR) T cell therapy has been highly effective in eradicating malignant B cells in cancer, and this success has prompted an extension of the approach to areas beyond oncology. In pioneering studies, CAR T cells targeting the B cell marker CD19 demonstrated robust efficacy as treatment for the autoimmune disease systemic lupus erythematosus.
Open in Who Shared Issue with article?

Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage - Nature Biotechnology

|
By Alessio David Nahmad, Asaf Madi, Uri Ben-David, Adi Barzel
| Nature Verified
Abstract Multiple clinical trials of allogeneic T cell therapy use site-specific nucleases to disrupt T cell receptor (TCR) and other genes1,2,3,4,5,6. In this study, using single-cell RNA sequencing, we investigated genome editing outcomes in primary human T cells transfected with CRISPR–Cas9 and guide RNAs targeting genes for TCR chains and programmed cell death protein 1.
Open in Who Shared Issue with article?

In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice - Nature Biotechnology

|
By Cicera R. Lazzarotto, Talia Kustin, Mary Tenuta, Deli Huang, Yaron Carmi, David Nemazee, James E. Voss, Adi Barzel, Alessio D. Nahmad, Rina Rosin-Arbesfeld
| Nature Verified
Abstract Transplantation of B cells engineered ex vivo to secrete broadly neutralizing antibodies (bNAbs) has shown efficacy in disease models. However, clinical translation of this approach would require specialized medical centers, technically demanding protocols and major histocompatibility complex compatibility of donor cells and recipients.
Open in Who Shared Issue with article?
See all 4 articles